TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

Core Insights - TFF Pharmaceuticals has announced positive preclinical data for a multivalent universal influenza vaccine using its patented Thin Film Freezing technology, showing promise in protecting against seasonal and pandemic influenza viruses [1][2][6] - The vaccine candidates have demonstrated the ability to induce neutralizing antibody titers in ferrets against H1 and H3 influenza strains, indicating high immunogenicity [2][3] - The ongoing studies aim to assess neutralizing antibody titers against a broader panel of influenza A viruses, with the goal of developing a shelf-stable mucosal vaccine that could be self-administered [4][5] Company Overview - TFF Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative drug products through its proprietary Thin Film Freezing technology, which allows for the transformation of drugs into dry powder formulations [7][8] - The company's TFF technology enhances the delivery of therapeutics, improving bioavailability and reducing side effects by allowing for direct delivery to target organs [7] - The potential success of the universal flu vaccine could lead to several billion dollars in annual sales, representing a significant out-licensing opportunity for the company [6]